Wyeth Pharmaceuticals announced a pilot program, Hemophilia Rapid Response Service, to help
hemophilia patients obtain better access to clotting factor in emergency rooms. The new program
will supply approximately 2,500 participating hospitals with Wyeth’s recombinant factor VIII
product ReFacto® and recombinant factor IX product, BeneFIX®, through a network of 25
pharmacies. After placing a call to the Rapid Response Service toll-free number, hospitals can
expect to receive factor product within three hours.
“We hope that the Hemophilia Rapid Response Service will provide patients and their loved ones
with a sense of confidence and relief that their clotting factor product can be available when they
need it most,” said Robert J. Dufour, Vice President and Global Business Manager, Hemophilia,
ReFacto® is indicated for the control and prevention of factor VIII hemorrhagic episodes. It is
also used for surgical prophylaxis and short-term routine prophylaxis to reduce the frequency of
spontaneous bleeding episodes in hemophilia A patients.
BeneFIX® is indicated for the control and prevention of hemorrhagic episodes in patients with
hemophilia B, including control and prevention of bleeding during surgery.
Source: Wyeth news release dated July 10, 2006